US 7,320,970 B2 | ||
Low dose estrogen interrupted hormone replacement therapy | ||
Robert F. Casper, Toronto (Canada); Gary A. Shangold, Califon, N.J. (US); and Militza K. Ausmanas, Lake Forest, Ill. (US) | ||
Assigned to Duramed Pharmaceutials, Inc., Cincinnati, Ohio (US); and Jencap Research Ltd., Toronto, Ontario (Canada) | ||
Filed on May 24, 2006, as Appl. No. 11/439,171. | ||
Application 11/439171 is a continuation of application No. 10/806613, filed on Mar. 22, 2004, granted, now 7,078,394, filed on Jul. 18, 2006. | ||
Application 10/806613 is a continuation of application No. 10/134455, filed on Apr. 30, 2002, granted, now 6,747,019, filed on Jun. 08, 2004. | ||
Application 10/134455 is a continuation of application No. 09/538485, filed on Mar. 30, 2000, abandoned. | ||
Claims priority of provisional application 60/126970, filed on Mar. 30, 1999. | ||
Prior Publication US 2006/0211663 A1, Sep. 21, 2006 | ||
This patent is subject to a terminal disclaimer. | ||
Int. Cl. A61K 31/56 (2006.01) |
U.S. Cl. 514—170 | 10 Claims |
1. A method of treating a female in need of hormone replacement therapy, the method comprising administering:
(a) three consecutive daily dosage forms or an equivalent thereof comprising a substance exhibiting estrogenic activity; followed
by
(b) three consecutive daily dosage forms or an equivalent thereof comprising a substance exhibiting estrogenic activity and
a substance exhibiting progestogenic activity equivalent to about 90 μg norgestimate per day.
|